- In Vitro Models for Drug Screening
Drug discovery is a process where a new drug or medications are discovered and aims to identify a compound therapeutically useful in curing and treating disease. It includes a wide range of scientific divisions, including biology, chemistry, and pharmacology.
This process associates with the identification of candidates, synthesis, characterization, validation, optimization, screening, and assays for therapeutic efficacy.
The three major phases are:
- Formulation,
- Delivery,
- Packaging Development
Drug Development Phases includes:
- Phase 1: Discovery and Development.
- Phase 2: Preclinical Research.
- Phase 3: Clinical Research.
- Phase 4: FDA Review.
- Phase 5: FDA Post-Market Safety Monitoring.
Drug screening is a process where potential drugs are identified and optimized before the selection of a candidate drug to progress to clinical trials. It can involve screening large volumes of chemicals for a particular biological activity in high-throughput screening assays.
Drug screening mainly includes In-vivo and In-vivo models for drug screening
Vladlen Slepak
University of Miami, United States
Yong Xiao Wang
Albany Medical College, United States
Axel H Schonthal
University of Southern California, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Madhav Bhatia
University of Otago, New Zealand
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Saad Tayyab
UCSI University, Malaysia
Anil Pareek
Anand Pharmacy College, India
Lan Wang
Paretor LLC, United States
Helen Cho
Samyang Biopharm Corporation, Korea, Republic ofSubmit your abstract Today
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico